On September 10, 2019 Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology to improve protein therapies for unmet patient needs, reported that Eef Schimmelpennink, President and Chief Executive Officer, and Susan Knudson, Chief Financial Officer, will be participating in one-on-one investor meetings at the Oppenheimer Fall Summit focused on specialty pharma and rare disease companies, taking place at the Parker Hotel in New York City on September 23rd – 24th (Press release, Pfenex, SEP 10, 2019, View Source [SID1234539434]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer & Co. Fall Summit

Date: September 24th

Format: One-on-One Meetings